newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//STAT
Supreme Court declines to take up lawsuits against Medicare drug price negotiation program.
The Supreme Court refused to hear lawsuits from major drug companies challenging Medicare price negotiations.
KEY POINTS
AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, and Novo Nordisk filed the suits.
All lower courts had ruled against the drugmakers prior to the Supreme Court's decision.
The Supreme Court's denial effectively leaves Medicare's drug price negotiation program in place.
WASHINGTON — The Supreme Court on Monday dealt a major blow to the brand drug industry’s legal campaign against the Medicare drug price negotiation program.
The court declined to take up lawsuits against the program by AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, and Novo Nordisk. The justices did not give a reason for their decision.
Advertisement
The rejection was not a surprise. The drugmakers lost their appeals in lower courts, and the Supreme Court typically does not take up cases when there is agreement among lower courts.